Show Summary Details
Page of

Genetic and Genomics in Clinical Hematology, III: Acute Leukemias 

Genetic and Genomics in Clinical Hematology, III: Acute Leukemias
Genetic and Genomics in Clinical Hematology, III: Acute Leukemias

Kenneth Mills

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 25 January 2021

Acute myeloid leukaemia (AML) is a genetically heterogeneous disorder characterized by arrest of differentiation in the myeloid lineage coupled with an accumulation of immature progenitors in the bone marrow, resulting in hematopoietic failure. AML is the most common form of acute leukemia in adults; AML accounts for only around 10% of paediatric leukemia cases. The cause of AML is unknown in most cases, but the development has been strongly linked to radiation, chemical exposure (benzene), or prior use of alkylating agents, working in the background of several genes predisposing to triggering leukemogenesis. Some AML patients have evolved from a prior hematological disorder, e.g., chronic myeloid leukemia (CML), Myelodysplastic syndrome (MDS) or myeloproliferative neoplasm. Patients with MDS may develop AML; approximately 25% of AML patients have a previous history of MDS, this leukemia are generally designated as secondary leukemia and are of interest due to the probable multiple genetic aberrations required for the evolution into AML. In recent years, an increasing number of gene mutations, deregulated expression of genes and noncoding RNAs (miRNAs) and epigenetic changes have been identified which has added to the molecular heterogeneity of the disease

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.